Application of entinstat in preparation of medicine for inhibiting vascular restenosis after interventional operation
The inhibition of HDAC enzyme by entestat can solve the problem of difficulty in screening for restenosis after vascular intervention, and effectively inhibition of vascular restenosis is achieved, providing a new drug solution.
Patent Information
- Application Number
- CN202411104178.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively screen out drugs that inhibit restenosis after vascular intervention, which leads to the problem of restenosis still serious, affecting the health and socio-economics of patients.
Entistat and its derivatives or modifications are used as drugs to inhibit angiogenesis and endometrial regeneration by inhibiting HDAC1, HDAC2 and HDAC3, thereby effectively inhibiting restenosis after vascular intervention.
Entestat can significantly inhibit endometrial neogenesis and proliferation and migration of vascular smooth muscle cells after vascular intervention, effectively preventing vascular restenosis, and providing a new drug choice to solve the problem of vascular restenosis.
Smart Images

Figure CN118903124A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug research and development, and specifically relates to the use of entinostat in preparing a drug for inhibiting post-interventional vascular restenosis. Background Art
[0002] Cardiovascular disease ranks first in all-cause mortality among human diseases. Among the numerous cardiovascular diseases, vascular stenosis or occlusive lesions caused by various factors are important causes of death from cardiovascular diseases. The development of endovascular treatment technology has achieved better treatment results for vascular stenosis or occlusive diseases, but the incidence of restenosis and the resulting need for repeated revascularization still occur at a rate of 1%-2% per year. Although drug-eluting stents and coated balloons can effectively reduce the incidence of restenosis, the one-year vascular restenosis rate is still as high as 17%, and the two-year restenosis rate is as high as 30-40%. Restenosis after endovascular treatment has prevented a large number of patients from being cured and causing them to lose their labor force or even die, which has a significant impact on the health of the people and social and economic development. It is a clinical problem that needs to be solved urgently.
[0003] At present, there are few new drugs developed solely for vascular restenosis. People usually screen existing drugs for drugs that have the effect of inhibiting vascular restenosis, which makes people's acquisition of drugs in this area extremely random.
[0004] In the new drug research and development activities, anti-tumor drugs are the key research and development direction. Generally speaking, anti-tumor drugs have the effect of inhibiting angiogenesis. When screening drugs to inhibit vascular restenosis, people have also considered screening among drugs that can affect angiogenesis. However, after a lot of exploration, people found that the effect of drugs that can affect angiogenesis in inhibiting vascular restenosis is often difficult to predict. For example, Gregory S et al. [1] found that although inhibition of MMP activity can reduce angiogenesis, it cannot prevent neointimal regeneration during angioplasty; Norika Mengchia Liu et al. [2] It was found that although netrin-1 can promote angiogenesis, it has an inhibitory effect on intimal neoplasia; for example, Mark J. Post et al. [3] It was found that although rFGF-2 has the effect of promoting angiogenesis, it has no significant effect on restenosis after angioplasty. In other words, people have not yet found a rule to follow in screening drugs that have the effect of inhibiting restenosis after vascular intervention.
[0005] The reason for the above situation may be that the causes of vascular restenosis caused by intimal neoplasia are relatively complex, and it is difficult to infer whether a drug has the effect of inhibiting vascular restenosis based on a certain effect (such as whether it promotes angiogenesis). Intimal neoplasia is a pathophysiological response to vascular injury, characterized by an increase in the number of cells, which leads to thickening of the vascular wall at the intimal level, followed by vascular lumen stenosis and blood flow restriction. There are many causes of intimal neoplasia, such as vascular wall injury, aging and inflammation, non-laminar shear stress, hypertension, etc., which may stimulate intimal neoplasia.
[0006] Therefore, how to screen out a new drug that can inhibit restenosis after vascular intervention is urgently needed in this field.
[0007] This section of the prior art reports:
[0008] [1]Cherr GS,Motew SJ,Travis JA,et al.Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates.[J].Arteriosclerosis Thrombosis&Vascular Biology,2002,22(1):161.DOI:10.1161 / hq0102.101129.
[0009] [2]Liu NM,Siu KL,Youn JY,et al.Attenuation of neointimal formation with netrin-1and netrin-1preconditioned endothelial progenitor cells[J].Journal of Molecular Medicine,2016,95(3):1-14.DOI:10.1007 / s00109-016-1490-4.
[0010] [3]Post MJ,Laham RJ,Kuntz RE,et al.The effect of intracoronaryfibroblast growth factor-2on restenosis after primary angioplasty or stentplacement in a pig model of atherosclerosis[J].Clinical Cardiology,2010,25(6):271-278.DOI:10.1002 / clc.4960250606. Summary of the invention
[0011] In view of the deficiencies of the prior art, the purpose of the present invention is to provide a new drug that has the effect of inhibiting restenosis after vascular intervention, and specifically to provide the use of entinostat in the preparation of a drug that has the effect of inhibiting restenosis after vascular intervention, in order to solve the problem that it is difficult to screen drugs that have the effect of inhibiting restenosis after vascular intervention from existing drugs.
[0012] In order to achieve the above object, the present invention provides the following solution.
[0013] Application of entinostat and its derivatives or modifications in the preparation of drugs for inhibiting vascular restenosis after vascular intervention.
[0014] The vascular interventional procedure includes any one of percutaneous transluminal angioplasty, vascular stent placement, arteriovenous fistula, percutaneous transluminal coronary angioplasty, carotid artery stenosis stenting, and intracranial vascular stenosis stent implantation.
[0015] The drug includes any one of an oral preparation, an injection, a stent or a balloon surface coating dosage form.
[0016] The drug includes pharmaceutical excipients in addition to entinostat.
[0017] Entinostat is an orally available HDAC class I inhibitor that inhibits HDAC1, HDAC2 and HDAC3, and exerts anti-tumor effects by inhibiting cell proliferation, promoting terminal differentiation and / or inducing apoptosis. Currently, the indications for Entinostat under development are: HR-positive / HER2-negative breast cancer, breast cancer, advanced breast cancer, recurrent breast cancer, HR-positive breast cancer, locally advanced breast cancer, metastatic breast cancer, lymphoma, metastatic melanoma, renal cell carcinoma, advanced renal cell carcinoma, metastatic non-small cell lung cancer, acute myeloid leukemia, male breast tumors, triple-negative breast cancer, advanced lymphoma, advanced malignant solid tumors, refractory B-cell lymphoma, metastatic pancreatic adenocarcinoma, pancreatic acinar carcinoma, refractory lymphoma, refractory malignant solid tumors, refractory T-cell lymphoma, mismatch repair defect or micro-high satellite instability colorectal cancer, metastatic renal cell carcinoma, bladder urothelial carcinoma stage IV, brain metastases and extensive-stage small cell lung cancer. To the best of the inventors' knowledge, no studies have been conducted on entinostat in the field of intimal neoplasia.
[0018] According to known studies, entinostat has the effect of inhibiting angiogenesis, such as APARNAMAITI [4] et al. found that it can enhance the expression of anti-angiogenic genes. The inventors found that entinostat has the effect of inhibiting vascular restenosis. This finding is consistent with the above-mentioned prior art reports. [1-3] The conclusions of the present invention are different or even opposite. Therefore, the discovery of the present invention is surprising.
[0019] Beneficial effects of the present invention:
[0020] Entinostat can effectively inhibit the degree of intimal regeneration after vascular intervention and the proliferation and migration of vascular smooth muscle cells after mechanical stretching, thereby effectively inhibiting vascular restenosis after vascular intervention.
[0021] This section of the prior art reports:
[0022] [4]Maiti, Qi, Peng, et al. Class I histone deacetylase inhibitorsuppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells[J]. International Journal of Oncology, 2019. DOI: 10.3892 / ijo.2019.4796. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The results of Western blotting and immunofluorescence experiments on the femoral popliteal artery to detect HDAC1 expression; Part A shows that Western blotting experiments detected that the expression of HDAC1 in the superficial femoral artery after endovascular treatment was higher than that in the superficial femoral artery of healthy people (n=8); Part B is a statistical graph of the results of Western blotting experiments; Part C shows that immunofluorescence experiments proved that the expression of HDAC1 in the superficial femoral artery after endovascular treatment was higher than that in the superficial femoral artery of healthy people (4×: means photographed under a 4× lens, the same below), in Part C, DAPI (blue fluorescence) shows the cell nucleus, α-SMA (green fluorescence) shows the vascular smooth muscle cells, and HDAC1 (red fluorescence) shows the expression of HDAC1.
[0024] Figure 2 The results of modeling the guidewire injury model of the femoral artery in mice; Part A is a diagram showing the successful modeling of the guidewire injury model of the femoral artery in mice; Part B shows the degree of intimal neoplasia detected by HE staining 2 weeks after guidewire injury of the femoral artery in mice (n=6) (40×); Part C is a statistical diagram of the degree of intimal neoplasia 2 weeks after guidewire injury of the femoral artery in mice (three different planes of the femoral artery of each mouse were cut for statistical analysis); (****P<0.0001).
[0025] Figure 3 The results of HDAC1 expression 24 hours and 2 weeks after the mouse femoral artery guidewire injury model are shown; HDAC1 expression increased 24 hours and 2 weeks after the mouse femoral artery guidewire injury (n=6) (40×); DAPI (blue fluorescence) shows the cell nucleus; green fluorescence shows the expression of HDAC1.
[0026] Figure 4 The results of the effect of entinostat on the expression of HDAC1 in various organs are shown in Figure 2; Part A shows that Western blotting experiments detected that entinostat can inhibit the expression of HDAC1 in the heart, liver, spleen, lung, kidney, and abdominal aorta of mice (n=6); Part B is a statistical graph of the results of Western blotting experiments (n=6) (* represents P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
[0027] Figure 5The results of entinostat inhibiting the neointimal regeneration after guidewire injury of the femoral artery in mice; the HE staining results in part A showed that entinostat could inhibit the neointimal regeneration 2 weeks after guidewire injury of the femoral artery in mice (n=6), and the immunofluorescence experiment showed that entinostat could inhibit the expression of HDAC1 in the femoral artery of mice (n=6) (40×); DAPI (blue fluorescence) showed the cell nucleus; green fluorescence showed the expression of HDAC1; part B was a statistical chart of HE staining detection that entinostat could inhibit the neointimal regeneration 2 weeks after guidewire injury of the femoral artery in mice (n=6) (three different planes were cut from the femoral artery of each mouse for statistical analysis); (****P<0.0001). Figure 6 The figure shows the results of primary vascular smooth muscle cell culture and detection; Part A shows the extraction and culture of primary vascular smooth muscle cells (4×); Part B shows the identification of primary vascular smooth muscle cells by immunofluorescence; DAPI (blue fluorescence) shows the cell nucleus; red fluorescence shows the expression of α-SMA (vascular smooth muscle cell marker protein) (10×).
[0028] Figure 7 The results of in vitro experiments on the effect of entinostat on the proliferation and migration of vascular smooth muscle cells after mechanical stretch; Part A shows the EdU experiment verifying that 250nM entinostat inhibits the proliferation of primary vascular smooth muscle cells caused by 10% mechanical stretch (10% MS) (10×); Hoechst (blue fluorescence) shows the cell nucleus, and red fluorescence shows EdU-labeled DNA, indicating that the cells are in a proliferative state; Part B is a statistical graph of the EdU experiment; Part C is a statistical graph of the CCK8 experiment verifying that 250nM entinostat inhibits the proliferation of primary vascular smooth muscle cells caused by 10% mechanical stretch (10% MS); Part D is a Transwell experiment verifying that 250nM entinostat inhibits the migration of primary vascular smooth muscle cells caused by 10% mechanical stretch (10% MS) (4×); Part E is a statistical graph of the Transwell experiment; (**P<0.01, ***P<0.001, ****P<0.0001). DETAILED DESCRIPTION
[0029] The present invention is described in detail below through examples. It is necessary to point out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by technical personnel in this field based on the above invention content still fall within the scope of protection of the present invention.
[0030] Example 1
[0031] This example is the result of a preliminary study. After the patient signed an informed consent form and the clinical trial ethics committee of the Affiliated Hospital of Southwest Medical University approved the example, healthy people (young patients injured in a car accident) and patients after endovascular treatment were selected to examine the femoral and popliteal arteries for Western blotting and immunofluorescence experiments to detect HDAC1 expression. The results are as follows Figure 1 shown.
[0032] like Figure 1 As shown in Part A and Part B, Western blotting assay detected that the expression of HDAC1 in the superficial femoral artery after endovascular treatment was higher than that in the superficial femoral artery of healthy subjects (n=8). Figure 1 As shown in part C, immunofluorescence experiments demonstrated that HDAC1 expression in the superficial femoral artery after endovascular treatment was higher than that in the superficial femoral artery of healthy subjects (4×).
[0033] The following is the specific experimental plan:
[0034] 1.1 Immunofluorescence experiment (IF) experimental materials and instruments:
[0035] 4% paraformaldehyde: purchased from Kashima Mall Luzhou Distribution Center (Solarbio / Solaibao), item number: P1110-500ml;
[0036] Triton X-100: purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., catalog number: T8787;
[0037] Bovine serum albumin (BSA): purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., catalog number: A1933-1G;
[0038] Anti-fluorescence quenching mounting medium (containing DAPI): Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0131-25ml;
[0039] Primary antibody HDAC1 Monoclonal antibody: purchased from Kashma Mall Luzhou Distribution Center, proteintech, catalog number: 66085-1-Ig;
[0040] Primary antibody Anti-alpha smooth muscle Actin RabbitpAb: purchased from Wuhan Saiweier Biotechnology Co., Ltd., catalog number: GB111364-100;
[0041] Donkey anti-rabbit fluorescent secondary antibody, Alexa Fluor 488: purchased from Invitrogen, catalog number: A-21206;
[0042] Donkey anti-mouse fluorescent secondary antibody, AlexaFluor 555: Invitrogen, catalog number: A-31570;
[0043] Upright fluorescence microscope: OLYMPUS.
[0044] 1.2 Immunofluorescence experiment (IF) experimental steps:
[0045] Human femoral arteries were frozen-embedded in OCT and frozen-sectioned with a thickness of 5 μm. The sections were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with 5% BSA, incubated with primary antibody at 4°C for 12 h, incubated with secondary antibody at 25°C for 1 h, stained with DAPI and blocked, and photographed under an immunofluorescence microscope.
[0046] 2.1WB experimental materials and instruments:
[0047] RIPA lysis buffer (strong): purchased from Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0013B;
[0048] PMSF: purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., catalog number: ST505;
[0049] BCA protein concentration determination kit: purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., catalog number: P0012;
[0050] SDS-PAGE protein loading buffer (5X): purchased from Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0015;
[0051] PAGE gel rapid preparation kit: purchased from Shanghai Yazyme Biotechnology Co., Ltd., catalog number: PG111
[0052] NC membrane: Merck millipore, catalog number: HATF00010
[0053] Skim milk powder: purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., item number: P0216-1500g
[0054] Primary antibody HDAC1 Monoclonal antibody: purchased from Kashma Mall Luzhou Distribution Center, proteintech, catalog number: 66085-1-Ig;
[0055] Beta Actin Monoclonal antibody: purchased from Kashma Mall Luzhou Distribution Center, proteintech, catalog number: 66009-1-lg
[0056] GAPDH Polyclonal Antibody: purchased from Kashma Mall Luzhou Distribution Center, proteintech, catalog number: 10494-1-AP
[0057] Goat anti-rabbit HRP secondary antibody: purchased from Invitrogen (Shanghai) Trading Co., Ltd., catalog number: C31460100
[0058] Sheep anti-mouse HRP secondary antibody: purchased from Invitrogen (Shanghai) Trading Co., Ltd., catalog number: C31430100
[0059] Omni-ECL TM Ultrasensitive chemiluminescence detection kit (femtogram level): purchased from Shanghai Yazyme Biotechnology Co., Ltd., catalog number: SQ201L;
[0060] Western primary and secondary antibody removal solution (strong alkaline): purchased from Shanghai Biotime Biotechnology Co., Ltd., product number: P0025-250ml.
[0061] 2.2WB experimental steps:
[0062] Take about 20 mg of tissue sample, add RIPA:PMSF:phosphatase inhibitor = 100:1:1, add steel beads (2-3) to the mixture, homogenize with a homogenizer, lyse on ice for 30 minutes, centrifuge at 4°C, 14000g for 15 minutes, and perform protein quantification according to the BCA protein quantification operating instructions. After adding the loading buffer, boil at 100°C for 10 minutes. After loading, concentrate the gel at 60V voltage. After separating the gel, use 120V voltage for SDS-PAGE electrophoresis, constant flow transfer, block with 5% skim milk powder, incubate with primary antibody HDAC1 at 4°C overnight, incubate with secondary antibody at room temperature for 2h, and develop with ECL. After eluting HDAC1 with Western primary antibody and secondary antibody removal buffer, incubate the internal reference protein BetaActin at 4°C overnight, incubate with secondary antibody at room temperature for 2h, and develop with ECL, and calculate the gray value.
[0063] Example 2
[0064] This example is an experiment to construct a mouse femoral artery guidewire injury model and investigate the extent of intimal regeneration after femoral artery guidewire injury in mice by Entinostat.
[0065] 1.1 Construction of mouse femoral artery guidewire injury model Experimental materials and instruments:
[0066] Mice: C57 / 6J male mice, 6 weeks old, were purchased from the Animal Experiment Center of Southwest Medical University. This experiment was approved by the Experimental Ethics Committee of Southwest Medical University (No.: 20240219-002).
[0067] SPF-grade rat maintenance feed was purchased from Huanyu Biotechnology Co., Ltd.;
[0068] Guidewire: Abbott CROSS-IT 200XT 0.014; the working diameter of the guidewire tip of this model is 0.25 mm, which is about 1.25-1.67 times the diameter of the normal mouse femoral artery (0.15-0.2 mm);
[0069] Isoflurane: purchased from Shenzhen Reward Life Science Co., Ltd., catalog number: R510-22-10;
[0070] Depilatory cream: purchased from Kashma Mall Luzhou Distribution Center, item number: WT-50.
[0071] 1.2 Experimental steps of mouse femoral artery guidewire injury model:
[0072] After stable isoflurane inhalation anesthesia, the mice were fixed on a sterile animal operating table to keep the airway open. The superficial femoral artery of the mice was freed under a stereomicroscope, and the deep femoral artery was protected. A curved thin needle was used to pre-puncture the superficial femoral artery to assist the guide wire to pass through the puncture point into the blood vessel. The guide wire was repeatedly advanced and retreated in the blood vessel three times to simulate the vascular trauma caused by clinical angioplasty. After withdrawing the guide wire, the proximal and distal ends of the puncture point were ligated. The sham operation group only underwent skin incision and vascular freeing, and the modeling was completed. After 24 hours and 2 weeks, the mice were killed by cervical dislocation and the femoral artery proximal to the puncture point was obtained. The expression of HDAC1 was detected by immunofluorescence experiment 24 hours and 2 weeks after the successful construction of the mouse femoral artery guidewire injury model. The results are shown in the figure. Figure 3 shown.
[0073] Entinostat was dissolved in PBS to 1 mg / ml and given to mice orally for 1 week. After the femoral artery was injured by a guidewire, it was continued to be given orally for 2 weeks. The samples included heart, liver, spleen, lung, kidney, abdominal aorta, and femoral artery. Western blotting experiments were used to verify the inhibitory effect of entinostat on HDAC1 in the heart, liver, spleen, lung, kidney, and abdominal aorta of mice; immunofluorescence experiments were used to verify the inhibitory effect of entinostat on HDAC1 in the femoral artery of mice; HE staining was used to detect the inhibitory effect of entinostat on the degree of neointimal regeneration in the femoral artery of mice. Figure 4 As shown in Figure 2, Western blotting experiments detected that entinostat could inhibit the expression of HDAC1 in the heart, liver, spleen, lung, kidney, and abdominal aorta of mice (n=6). Figure 5 As shown, HE staining detected that entinostat could inhibit the neointimal regeneration 2 weeks after guidewire injury in the femoral artery of mice (n=6), and immunofluorescence assay detected that entinostat could inhibit the expression of HDAC1 in the femoral artery of mice (n=6) (40×).
[0074] 2.1 HE staining experimental materials and instruments:
[0075] OCT frozen section embedding medium: purchased from Luzhou Saiens Biotechnology Co., Ltd., catalog number: 4583;
[0076] Hematoxylin and eosin (HE) staining kit: purchased from Sangon Biotech (Shanghai) Co., Ltd., catalog number: E607318-0200;
[0077] Digital slide scanner: Southwest Medical University Pathology Platform, model: KF-PRO-002.
[0078] 2.2 HE staining experimental steps:
[0079] After the successful establishment of the mouse femoral artery guidewire injury model, the mouse femoral artery was obtained 24 hours and 2 weeks later for OCT cryo-embedding and frozen sectioning with a thickness of 5 μm. The sections were fixed for 30 seconds to 1 minute, washed with water, stained with hematoxylin for 3-5 minutes, blued in alkaline water for 20 seconds, stained with eosin for 10-20 seconds, dehydrated, transparent, and sealed with neutral gum, and digitally sliced and scanned.
[0080] 3.1 Immunofluorescence experiment (IF) experimental materials and instruments:
[0081] 4% paraformaldehyde: purchased from Kashima Mall Luzhou Distribution Center (Solarbio / Solaibao), item number: P1110-500ml;
[0082] Triton X-100: purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., catalog number: T8787;
[0083] Bovine serum albumin (BSA): purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., catalog number: A1933-1G;
[0084] Anti-fluorescence quenching mounting medium (containing DAPI): Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0131-25ml;
[0085] Primary antibody HDAC1 Monoclonal antibody: purchased from Kashma Mall Luzhou Distribution Center, proteintech, catalog number: 66085-1-Ig;
[0086] Donkey anti-mouse fluorescent secondary antibody, AlexaFluor 488: purchased from Guangzhou Guihai Biotechnology Co., Ltd. (Invitrogen), catalog number: A21202;
[0087] Upright fluorescence microscope: OLYMPUS.
[0088] 3.2 Immunofluorescence experiment (IF) experimental steps:
[0089] After the successful establishment of the mouse femoral artery guidewire injury model, the mouse femoral artery was obtained 24 hours and 2 weeks later for OCT cryo-embedded and frozen sections with a thickness of 5 μm. The sections were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with 5% BSA, incubated with primary antibody at 4°C for 12 hours, incubated with secondary antibody at 25°C for 1 hour, stained with DAPI and blocked, and photographed under an immunofluorescence microscope.
[0090] 4.1WB experimental materials and instruments:
[0091] RIPA lysis buffer (strong): purchased from Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0013B;
[0092] PMSF: purchased from Shanghai Biotime Biotechnology Co., Ltd., catalog number: ST505; BCA protein concentration assay kit: purchased from Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0012;
[0093] SDS-PAGE protein loading buffer (5X): purchased from Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0015;
[0094] PAGE gel rapid preparation kit: purchased from Shanghai Yazyme Biotechnology Co., Ltd., catalog number: PG111;
[0095] NC membrane: Merck millipore, catalog number: HATF00010;
[0096] Skim milk powder: purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., product number: P0216-1500g;
[0097] Primary antibody HDAC1 Monoclonal antibody: purchased from Kashma Mall Luzhou Distribution Center, proteintech, catalog number: 66085-1-Ig;
[0098] Beta Actin Monoclonal antibody: purchased from Kashma Mall Luzhou Distribution Center, Proteintech, catalog number: 66009-1-lg;
[0099] GAPDH Polyclonal Antibody: purchased from Kashma Mall Luzhou Distribution Center, proteintech, catalog number: 10494-1-AP;
[0100] Goat anti-mouse HRP secondary antibody: purchased from Invitrogen (Shanghai) Trading Co., Ltd., catalog number: C31430100;
[0101] Omni-ECL TMUltrasensitive chemiluminescence detection kit (femtogram level): purchased from Shanghai Yazyme Biotechnology Co., Ltd., catalog number: SQ201L;
[0102] Western primary and secondary antibody removal solution (strong alkaline): purchased from Shanghai Biotime Biotechnology Co., Ltd., product number: P0025-250ml.
[0103] 4.2WB experimental steps:
[0104] Take about 20 mg of tissue sample, add RIPA:PMSF:phosphatase inhibitor = 100:1:1, add steel beads (2-3) to the mixture, homogenize with a homogenizer, lyse on ice for 30 minutes, centrifuge at 4°C, 14000g for 15 minutes, perform protein quantification according to the BCA protein quantification operating instructions, add loading buffer and boil at 100°C for 10 minutes, concentrate gel at 60V voltage after loading, and use 120V voltage for SDS-PAGE electrophoresis after separation gel, constant flow transfer, 5% skim milk powder blocking, incubate with primary antibody HDAC1 at 4°C overnight, incubate with secondary antibody at room temperature for 2h, and develop with ECL. After eluting HDAC1 with Western primary antibody and secondary antibody removal solution, incubate with internal reference proteins BetaActin and GAPDH at 4°C overnight, incubate with secondary antibody at room temperature for 2h, and develop with ECL, and calculate the gray value.
[0105] Example 3
[0106] This example is an in vitro experiment to evaluate the ability of entinostat to inhibit the proliferation and migration of vascular smooth muscle cells after mechanical stretch.
[0107] 1.1 Experimental materials and instruments for mechanical stretch cell model:
[0108] Elastic chamber C802: purchased from Naturethink;
[0109] Gelatin: purchased from Beijing Solebow Technology Co., Ltd., product number: G8061-500g;
[0110] Entinostat: purchased from Guangzhou Zuoke Biotechnology Development Co., Ltd., MedChemExpress, catalog number: HY-12163-50mg;
[0111] Bio-Time trypsin cell digestion solution (0.25% trypsin), containing EDTA: purchased from Luzhou Xinkesheng Biotechnology Co., Ltd., product number: C0201-100ml;
[0112] Special grade fetal bovine serum (FBS): purchased from Sichuan Xinbiao Biotechnology Co., Ltd., catalog number: AC03L055;
[0113] Penicillin-streptomycin-amphotericin B: purchased from Kashma Mall Luzhou Distribution Center (Beyotime / Biyuntian), item number: C0224-100ml;
[0114] DMEM / F12 culture medium: purchased from Kashma Mall Luzhou Distribution Center (Gibco service), catalog number: C11330500BT;
[0115] Cell culture incubator: Thermo Fisher i160 cell culture incubator.
[0116] 1.2 Experimental steps of mechanical stretch cell model:
[0117] Balloon dilatation or stent implantation during intravascular treatment of arterial vessels will cause transient or continuous mechanical stretching of the narrowed or occluded blood vessels. The inventor used the elastic chamber C802 system to construct an in vitro cell experimental model that simulates mechanical stretching. The elastic dish provided by the system can cause the adherent cells to produce continuous stretching of varying degrees within a certain period of time under the action of external force. The elastic dish is an elastic silicone dish-shaped device that can be uniformly stretched by a matching stretching ruler and can be deformed and stretched by 5%, 10%, and 20%. The inventor first used PBS to prepare 1.5% gelatin and placed it in an elastic dish to facilitate cell adhesion and growth. After 24 hours of seeding the cultured primary vascular smooth muscle cells in the elastic dish, the elastic dish was placed on the stretching ruler for 5%, 10%, and 20% mechanical stretching for 2 minutes to simulate the mechanical stretching caused by intravascular treatment. The inventors studied the effects of different degrees of mechanical stretch on the proliferation and migration of primary vascular smooth muscle cells, and finally determined that 10% mechanical stretch was the best experimental condition. Based on this, the inventors used 250nM entinostat and found that entinostat can inhibit the proliferation and migration of primary vascular smooth muscle cells after mechanical stretch. Figure 7 shown.
[0118] 2.1 Extraction and culture of primary vascular smooth muscle cells Experimental materials and instruments:
[0119] Experimental animals: C57 / 6J male mice, 6 weeks old, were purchased from the Animal Experiment Center of Southwest Medical University. This experiment was approved by the Experimental Ethics Committee of Southwest Medical University (No.: 20240219-002).
[0120] SPF-grade rat maintenance feed was purchased from Huanyu Biotechnology Co., Ltd.;
[0121] Special grade fetal bovine serum: purchased from Sichuan Xinbiao Biotechnology Co., Ltd., catalog number: AC03L055;
[0122] Penicillin-streptomycin-amphotericin B: purchased from Kashma Mall Luzhou Distribution Center (Beyotime / Biyuntian), item number: C0224-100ml;
[0123] DMEM / F12 culture medium: purchased from Kashma Mall Luzhou Distribution Center (Gibco service), catalog number: C11330500BT;
[0124] 707003, T25 cell culture flask, breathable cap, TC (box): purchased from Kashma Mall Luzhou Distribution Center, NEST / Nest, item number: 707003
[0125] Cell culture incubator: Thermo Fisher i160 cell culture incubator.
[0126] 2.2 Experimental steps for extraction and culture of primary vascular smooth muscle cells:
[0127] Six-week-old C57 / 6J male mice were selected, and the entire aorta was isolated under sterile conditions. The connective tissue was removed on a clean bench. The blood vessels were longitudinally cut open to remove impurities such as endothelial cells, lipid droplets, blood clots, and possible residual endothelial cells and adventitial fibroblasts. The media tissue of the blood vessels was retained and cut into 1 mm 2 For tissue blocks of different sizes, place the cut tissue blocks evenly at the bottom of the bottle, with a spacing of 0.5 cm between the tissue blocks. Place the tissue blocks in a 37°C incubator for 2-4 hours to allow the tissue blocks to dry and adhere to the bottle wall, then flip them over and lay them flat, so that the tissue blocks are completely immersed in the culture medium, and continue to culture them for 3-5 days. After cells crawl out from around the tissue blocks, change the medium, select primary vascular smooth muscle cells of the P4-P7 generations, and identify them as MOVAS through α-SMA staining in immune cell experiments for subsequent experiments.
[0128] 3.1 Immune cell experiment (ICC) experimental materials and instruments:
[0129] 4% paraformaldehyde: purchased from Kashima Mall Luzhou Distribution Center (Solarbio / Solaibao), item number: P1110-500ml;
[0130] Triton X-100: purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., catalog number: T8787;
[0131] Bovine serum albumin (BSA): purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., catalog number: A1933-1G;
[0132] Anti-fluorescence quenching mounting medium (containing DAPI): Shanghai Biotime Biotechnology Co., Ltd., catalog number: P0131-25ml;
[0133] Primary antibody Anti-alpha smooth muscle Actin RabbitpAb: purchased from Wuhan Saiweier Biotechnology Co., Ltd., catalog number: GB111364-100;
[0134] Donkey anti-rabbit fluorescent secondary antibody, AlexaFluor 555: purchased from Guangzhou Guihai Biotechnology Co., Ltd. (Invitrogen), catalog number: A31572;
[0135] Upright fluorescence microscope: OLYMPUS;
[0136] 6-well cell culture plate (paper plastic bag) / 6-well culture plate / 6-well plate: purchased from Luzhou Xinkesheng Biotechnology Co., Ltd., catalog number: TCP010006;
[0137] Bio-Time trypsin cell digestion solution (0.25% trypsin), containing EDTA: purchased from Luzhou Xinkesheng Biotechnology Co., Ltd., product number: C0201-100ml.
[0138] 3.2 Experimental steps of immune cell experiment:
[0139] Primary vascular smooth muscle cells were plated in 6-well plates. When the cell density reached 90%, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% TritonX-100, blocked with 5% BSA, incubated with primary antibody at 4°C for 12h, incubated with secondary antibody at 25°C for 1h, blocked after DAPI staining, and photographed under an immunofluorescence microscope. The primary antibody Anti-alpha smoothmuscleActin was used to identify primary vascular smooth muscle cells.
[0140] 4.1CCK8 experimental materials and instruments:
[0141] CCK8 kit: purchased from DOJINDO / Tongren Chemical, catalog number: CK04.
[0142] 4.2CCK8 experimental steps:
[0143] 1. Preparation of cell suspension: Take primary vascular smooth muscle cells in the logarithmic growth phase (grouped as: Ctrl, 10% MS, 10% MS + 250nM Entinostat, 250nM Entinostat), wash once with PBS, digest the cells with trypsin, centrifuge at 800rpm for 3min to precipitate the cells and discard the supernatant, add 1ml of 10% FBSDMEM / F12 culture medium to resuspend the cells, count the cells, and adjust the concentration to 1×10 4 Pieces / ml;
[0144] 2. Inoculate cells in 96-well plates, 1×10 3 / well, grouped as: Ctrl, 10% MS, 10% MS + 250nM Entinostat, 250nM Entinostat);
[0145] 3. After 24 hours, add 10 μL of the cell counting kit-8 solution to 100 μL of cell culture medium. After incubation at 37°C for 2 hours, measure the absorbance at 450 nm using an enzyme marker.
[0146] 5.1 EdU experimental materials and instruments:
[0147] Special grade fetal bovine serum (FBS): purchased from Sichuan Xinbiao Biotechnology Co., Ltd., catalog number: AC03L055;
[0148] Penicillin-streptomycin-amphotericin B: purchased from Kashma Mall Luzhou Distribution Center (Beyotime / Biyuntian), item number: C0224-100ml;
[0149] DMEM / F12 culture medium: purchased from Kashma Mall Luzhou Distribution Center (Gibco service), catalog number: C11330500BT;
[0150] Bio-Time trypsin cell digestion solution (0.25% trypsin), containing EDTA: purchased from Luzhou Xinkesheng Biotechnology Co., Ltd., product number: C0201-100ml;
[0151] Cell culture incubator: Thermo Fisher i160;
[0152] 4% paraformaldehyde: purchased from Kashima Mall Luzhou Distribution Center (Solarbio / Solaibao), item number: P1110-500ml;
[0153] Triton X-100: purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., catalog number: T8787;
[0154] EdU cell proliferation detection kit: purchased from Sangon Biotech (Shanghai) Co., Ltd., catalog number: E607204-0100
[0155] DMSO dimethyl sulfoxide: purchased from Benyuansheng Experimental Equipment Business Department, Jiangyang District, Luzhou City, item number: D4540FZ.
[0156] 5.2EdU experimental steps:
[0157] 1. Preparation of cell suspension: Take primary vascular smooth muscle cells in the logarithmic growth phase (grouped as: Ctrl, 10% MS, 10% MS + 250nM Entinostat, 250nM Entinostat), wash once with PBS, digest the cells with trypsin, centrifuge at 800rpm for 3min to precipitate the cells and discard the supernatant, add 1ml of 10% FBSDMEM / F12 culture medium to resuspend the cells, count the cells, and adjust the concentration to 1×10 4 Pieces / ml;
[0158] 2. Inoculate cells in 24-well plates, 1×10 4 / well, grouped as: Ctrl, 10% MS, 10% MS + 250nM Entinostat, 250nM Entinostat);
[0159] 3. 24 hours after the cells were plated, follow the steps of the Edu kit as follows:
[0160] Add EdU-containing culture medium to each well and incubate the cells for 2 hours; discard the culture medium, wash the cells twice with 1X PBS, 5 minutes each time to remove EdU residues not incorporated into DNA; add 4% paraformaldehyde cell fixative, incubate at room temperature for 30 minutes, and discard the fixative; incubate on a shaker with 2mg / ml glycine for 5 minutes to neutralize excess paraformaldehyde; wash with PBS solution at room temperature for 5 minutes; permeabilize with 0.5% Triton X-100 cell permeabilization solution at room temperature for 10 minutes, and discard the cell permeabilization solution; wash with PBS solution at room temperature for 5 minutes; add the prepared detection mixture to cover the cells, incubate at room temperature for 30 minutes in the dark; discard the staining reaction solution, wash 2 to 3 times with 0.5% Triton X-100 cell permeabilization solution, 10 minutes each time; wash twice with PBS, 5 minutes each time; add 1X Hoechst staining solution, incubate at room temperature in the dark for 20 to 30 minutes, and discard the staining solution; wash the cells twice with PBS and remove the washing solution; take pictures.
[0161] 6.1 Transwell experimental materials and instruments:
[0162] Bio-Time trypsin cell digestion solution (0.25% trypsin), containing EDTA: purchased from Luzhou Xinkesheng Biotechnology Co., Ltd., product number: C0201-100ml;
[0163] Special grade fetal bovine serum (FBS): purchased from Sichuan Xinbiao Biotechnology Co., Ltd., catalog number: AC03L055;
[0164] Penicillin-streptomycin-amphotericin B: purchased from Kashma Mall Luzhou Distribution Center (Beyotime / Biyuntian), item number: C0224-100ml;
[0165] DMEM / F12 culture medium: purchased from Kashma Mall Luzhou Distribution Center (Gibco service), catalog number: C11330500BT;
[0166] Cell culture incubator: Thermo Fisher Scientific i160.
[0167] Transwell-membrane nested transparent, 8um, 24-well plate: purchased from Benyuansheng Experimental Equipment Business Department, Jiangyang District, Luzhou City, Corning / Corning, catalog number: 3422
[0168] 4% paraformaldehyde: purchased from Kashima Mall Luzhou Distribution Center (Solarbio / Solaibao), item number: P1110-500ml;
[0169] Beyotime C0121 crystal violet staining solution: purchased from Guangzhou Shuoheng Biotechnology Co., Ltd., Beyotime / Beyotime (distributor), item number: C0121
[0170] DMSO dimethyl sulfoxide: purchased from Benyuansheng Experimental Equipment Business Department, Jiangyang District, Luzhou City, item number: D4540FZ
[0171] Microscope: OLYMPUS.
[0172] 6.2 Transwell Experimental Steps:
[0173] 1. Preparation of cell suspension: Take primary vascular smooth muscle cells in the logarithmic growth phase (grouped as: Ctrl, 10% MS, 10% MS + 250nM Entinostat, 250nM Entinostat), wash once with PBS, digest the cells with trypsin, centrifuge at 800rpm for 3min to precipitate the cells and discard the supernatant, add 1ml serum-free culture medium to resuspend the cells, count, and adjust the concentration to 1×10 4 Pieces / ml.
[0174] 2. Inoculate cells: Add 300 μl of cell suspension into the upper chamber of the transwell.
[0175] 3. Cultivate cells: Add 700 μl of complete culture medium containing 10% FBS to the lower chamber of the transwell, place in the incubator and culture for 24 hours before taking out.
[0176] 4. Fix the cells: Use a cotton swab to gently wipe off the cells in the upper chamber, discard the upper liquid of the transwell chamber, and soak it in 4% paraformaldehyde for 15 minutes.
[0177] 5. Wash the chamber three times with PBS (slowly shake for 5 minutes each time), stain with 0.1% crystal violet at room temperature for 15 minutes, and then wash three times with PBS;
[0178] 6. Take the stained chamber to the outside 50ml centrifuge tube and rinse it with PBS; use a cotton swab to remove the unpenetrated cells on the upper layer of the chamber;
[0179] 7. Observe and take photos under a microscope.
Claims
1. Use of entinostat and its derivatives or modifications in the preparation of drugs for inhibiting vascular restenosis after vascular intervention.
2. The use according to claim 1, It is characterized in that The vascular interventional procedure includes any one of percutaneous transluminal angioplasty, vascular stent placement, arteriovenous fistula, percutaneous transluminal coronary angioplasty, carotid artery stenosis stenting, and intracranial vascular stenosis stent implantation.
3. The use according to claim 1, It is characterized in that The drug includes any one of an oral preparation, an injection, a stent or a balloon surface coating dosage form.
4. The use according to claim 1, It is characterized in that The drug includes pharmaceutical excipients in addition to entinostat.
Citation Information
Patent Citations
Stents capable of controllably releasing histone deacetylase inhibitors
US20050065596A1
Cited By
Application of medicine for inhibiting NEK7 in preparation of medicine for inhibiting phenotypic transformation of smooth muscle cells and improving neointimal neogenesis
CN121226395A
